Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI United Kingdom (FTSE) vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.91 (market cap $3.71B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 2.3× iShares MSCI United Kingdom (FTSE)'s market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI United Kingdom (FTSE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 48 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EWU | HNGE | |
|---|---|---|
Market Cap | $3.71B | $8.47B |
Volume | 728,527 | 1,624,526 |
Sector | Broad Market / Factor | Health |
52-Week High | $49.39 | $105.14 |
52-Week Low | $41.34 | $31.17 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWU trades at $46.82 with a modest 0.26% daily gain, though technical indicators signal a bearish trend with moving averages and overall momentum pointing downward. The stock faces headwinds from UK economic concerns including rising gilt yields and inflation pressures. Recent news highlights sector-specific volatility in UK banking and housing markets, creating a challenging environment for this UK-focused ETF.
The outlook remains cautious given macroeconomic pressures on UK assets. Investment opportunity exists for contrarian investors betting on UK recovery, but risks include persistent inflation, rising interest rates, and political uncertainty around upcoming budget decisions that could impact financial and housing sectors significantly.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI United Kingdom (FTSE)
EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
